Showing results (61-70 of 73) with videos related to
Sort By:
Pageof 8
Research and Practice in Thrombosis and Haemostasis|April 1, 2024
Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studiesJohnny Mahlangu, Víctor Jiménez-Yuste, Giuliana Ventriglia, et al.Research and Practice in Thrombosis and Haemostasis|January 29, 2024
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeksAnna Kiialainen, Joanne I Adamkewicz, Claire Petry, et al.Research and Practice in Thrombosis and Haemostasis|November 18, 2022
Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY)Víctor Jiménez-Yuste, Flora Peyvandi, Robert Klamroth, et al.Molecular Psychiatry|February 4, 2026
Novel selective morpholine trace amine-associated receptor 1 partial agonists show promising preclinical effects for neuropsychiatric disorders and are well tolerated in healthy volunteersCéline Fournier, Danièle Buchy, Susanne Mohr, et al.The New England Journal of Medicine|July 11, 2017
Emicizumab Prophylaxis in Hemophilia A with InhibitorsJohannes Oldenburg, Johnny N Mahlangu, Benjamin Kim, et al.Blood|November 8, 2019
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitorsGuy Young, Ri Liesner, Tiffany Chang, et al.Blood|December 21, 2023
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trialSteven W Pipe, Peter Collins, Christophe Dhalluin, et al.The Lancet. Haematology|January 30, 2023
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 studyClaude Négrier, Johnny Mahlangu, Michaela Lehle, et al.The Lancet. Haematology|April 21, 2019
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 studySteven W Pipe, Midori Shima, Michaela Lehle, et al.The New England Journal of Medicine|August 30, 2018
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsJohnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, et al.Pageof 8